Answers are grounded in this paper and cite their sources.
Demonstrates efficient aerosol delivery and sustained release of simvastatin via lipid-core nanocapsules, indicating a promising inhalation platform.
Aims: Lipid-core nanocapsules (LNCs) loaded with simvastatin (SV, SV-LNC) or lovastatin (LV, LV-LNC) were formulated for pulmonary administration.Methods: The LNC suspensions were characterized physicochemically, their stability was evaluated, and drug delivery by the pulmonary route was tested in vitro.Results: The loaded LNCs had a particle size close to 200 nm, a low polydispersity index, and a zeta potential around −20 mV. The encapsulation efficiency was high for SV (99.21 ± 0.7%) but low for LV (20.34 ± 1.2%). SV release from nanocapsules was slower than it was from SV in solution, with a monoexponential release profile, and the drug emitted and aerosol output rate was higher for SV-LNCs (1.58 µg/s) than for SV in suspension (0.54 µg/s).Conclusions: SV-LNCs had a median aerodynamic diameter of 3.51 µm and a highly respirable fraction (61.9%), indicating that nanoparticles are a suitable system for efficient delivery of simvastatin to the lung.
No takes yet. Share an insight, caveat, or question.
Lorenzoni et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: